6 analysts have expressed a variety of opinions on Pharming (NASDAQ:PHAR) over the past quarter, offering a diverse set of opinions from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

	Bullish	Somewhat Bullish
Total Ratings	5	1
Last 30D	1	0
1M Ago	0	0
2M Ago	3	1
3M Ago	1	0

Analysts have recently evaluated Pharming and provided 12-month price targets. The average target is $32.0, accompanied by a high estimate of $37.00 and a low estimate of $14.00. This current average has decreased by 10.61% from the previous average price target of $35.80.

price target chart

Understanding Analyst Ratings: A Comprehensive Breakdown

In examining recent analyst actions, we gain insights into how financial experts perceive Pharming. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Lucy Codrington	Jefferies	Announces	Buy	$14.00	-
Michael Carrier	Oppenheimer	Lowers	Outperform	$30.00	$31.00
Joseph Pantginis	HC Wainwright & Co.	Maintains	Buy	$37.00	$37.00
Joseph Pantginis	HC Wainwright & Co.	Maintains	Buy	$37.00	$37.00
Joseph Pantginis	HC Wainwright & Co.	Maintains	Buy	$37.00	$37.00
Joseph Pantginis	HC Wainwright & Co.	Maintains	Buy	$37.00	$37.00

Key Insights:

Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pharming. This information offers a snapshot of how analysts perceive the current state of the company.
Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Pharming compared to the broader market.
Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Pharming's stock. This comparison reveals trends in analysts' expectations over time.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Pharming's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Pharming analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Delving into Pharming's Background

Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.

A Deep Dive into Pharming's Financials

Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.

Revenue Growth: Pharming displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 12.28%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1.38%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Pharming's ROE stands out, surpassing industry averages. With an impressive ROE of -0.46%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.25%, the company showcases effective utilization of assets.

Debt Management: With a high debt-to-equity ratio of 0.56, Pharming faces challenges in effectively managing its debt levels, indicating potential financial strain.

How Are Analyst Ratings Determined?

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Lucy Codrington's Stock Ratings

Overall Average Return

Smart Score

Overall Average Return Percentile

Number of Ratings

Recent Analyst Stock Rating News